Mersana Therapeutics Inc. [NASDAQ: MRSN] loss -1.66% or -0.11 points to close at $6.52 with a heavy trading volume of 3441097 shares. The company report on January 5, 2022 that Mersana Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference.
Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. ET.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 30 days following the presentation.
It opened the trading session at $6.82, the shares rose to $7.00 and dropped to $6.27, the range by which the price of stock traded the whole day. The daily chart for MRSN points out that the company has recorded -49.38% loss over the past six months. However, it is still -34.71% lower than its most recent low trading price.
If we look at the average trading volume of 830.82K shares, MRSN reached to a volume of 3441097 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Mersana Therapeutics Inc. [MRSN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRSN shares is $22.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRSN stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Mersana Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 15, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on August 30, 2021, representing the official price target for Mersana Therapeutics Inc. stock. Previously, the target price had yet another raise to $18, while Credit Suisse analysts kept a Neutral rating on MRSN stock.
The Average True Range (ATR) for Mersana Therapeutics Inc. is set at 0.52, with the Price to Sales ratio for MRSN stock in the period of the last 12 months amounting to 11218.95. The Price to Book ratio for the last quarter was 3.00.
Trading performance analysis for MRSN stock
Mersana Therapeutics Inc. [MRSN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.87. With this latest performance, MRSN shares gained by 5.33% in over the last four-week period, additionally sinking by -49.38% over the last 6 months – not to mention a drop of -64.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRSN stock in for the last two-week period is set at 50.57, with the RSI for the last a single of trading hit 56.97, and the three-weeks RSI is set at 46.39 for Mersana Therapeutics Inc. [MRSN]. The present Moving Average for the last 50 days of trading for this stock 7.32, while it was recorded at 6.46 for the last single week of trading, and 11.54 for the last 200 days.
Mersana Therapeutics Inc. [MRSN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Mersana Therapeutics Inc. [MRSN] shares currently have an operating margin of -10641.30. Mersana Therapeutics Inc.’s Net Margin is presently recorded at -10633.45.
Return on Total Capital for MRSN is now -53.18, given the latest momentum, and Return on Invested Capital for the company is -53.87. Return on Equity for this stock declined to -57.47, with Return on Assets sitting at -46.23. When it comes to the capital structure of this company, Mersana Therapeutics Inc. [MRSN] has a Total Debt to Total Equity ratio set at 7.38. Additionally, MRSN Total Debt to Total Capital is recorded at 6.88, with Total Debt to Total Assets ending up at 6.16. Long-Term Debt to Equity for the company is recorded at 6.71, with the Long-Term Debt to Total Capital now at 6.25.
Reflecting on the efficiency of the workforce at the company, Mersana Therapeutics Inc. [MRSN] managed to generate an average of -$800,409 per employee.Mersana Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.50 and a Current Ratio set at 4.50.
An analysis of insider ownership at Mersana Therapeutics Inc. [MRSN]
There are presently around $467 million, or 98.00% of MRSN stock, in the hands of institutional investors. The top three institutional holders of MRSN stocks are: BLACKROCK INC. with ownership of 8,807,328, which is approximately -0.174% of the company’s market cap and around 0.60% of the total institutional ownership; AVORO CAPITAL ADVISORS LLC, holding 6,800,000 shares of the stock with an approximate value of $45.08 million in MRSN stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $39.83 million in MRSN stock with ownership of nearly -12.65% of the company’s market capitalization.
Positions in Mersana Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 57 institutional holders increased their position in Mersana Therapeutics Inc. [NASDAQ:MRSN] by around 8,166,671 shares. Additionally, 66 investors decreased positions by around 8,287,359 shares, while 19 investors held positions by with 53,941,738 shares. The mentioned changes placed institutional holdings at 70,395,768 shares, according to the latest SEC report filing. MRSN stock had 12 new institutional investments in for a total of 2,731,134 shares, while 32 institutional investors sold positions of 4,432,979 shares during the same period.